Revance Therapeutics, Inc. News Releases https://investors.revance.com/ Revance Therapeutics, Inc. News Releases en Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference https://investors.revance.com/news-releases/news-release-details/revance-participate-rbc-capital-markets-2019-healthcare NEWARK, Calif. --(BUSINESS WIRE)--May 14, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019 Tue, 14 May 2019 16:05:00 -0400 Revance Therapeutics, Inc. News Releases 10556 Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update https://investors.revance.com/news-releases/news-release-details/revance-reports-first-quarter-2019-financial-results-and - Conference call and webcast today at 4:30 p.m. ET - NEWARK, Calif. --(BUSINESS WIRE)--May 8, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today reported financial Wed, 08 May 2019 16:05:00 -0400 Revance Therapeutics, Inc. News Releases 10506 Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019 https://investors.revance.com/news-releases/news-release-details/revance-release-first-quarter-2019-financial-results-wednesday Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET NEWARK, Calif. --(BUSINESS WIRE)--Apr. 24, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today Wed, 24 Apr 2019 16:05:00 -0400 Revance Therapeutics, Inc. News Releases 10496 Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing https://investors.revance.com/news-releases/news-release-details/revance-appoints-former-allergan-marketing-veteran-taryn-conway NEWARK, Calif. --(BUSINESS WIRE)--Apr. 9, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced a pivotal addition to its leadership team with the appointment of Tue, 09 Apr 2019 08:00:00 -0400 Revance Therapeutics, Inc. News Releases 10481 SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference https://investors.revance.com/news-releases/news-release-details/sakura-3-trial-results-presented-podium-worlds-largest-medical – Unprecedented clinical results for DaxibotulinumtoxinA for Injection (DAXI), Revance’s long-acting neuromodulator, were highlighted at the 17 th Aesthetics & Anti-Aging Medical World Congress in Monte-Carlo – NEWARK, Calif. --(BUSINESS WIRE)--Apr. 8, 2019-- Revance Therapeutics, Inc. Mon, 08 Apr 2019 16:05:00 -0400 Revance Therapeutics, Inc. News Releases 10476 Revance to Participate in the Needham Healthcare Conference https://investors.revance.com/news-releases/news-release-details/revance-participate-needham-healthcare-conference-0 NEWARK, Calif. --(BUSINESS WIRE)--Apr. 2, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Tue, 02 Apr 2019 16:05:00 -0400 Revance Therapeutics, Inc. News Releases 10471 Revance to Participate in Upcoming Investor Conferences https://investors.revance.com/news-releases/news-release-details/revance-participate-upcoming-investor-conferences-7 NEWARK, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor Tue, 05 Mar 2019 16:05:00 -0500 Revance Therapeutics, Inc. News Releases 10426 Revance Releases Fourth Quarter and Full Year 2018 Results https://investors.revance.com/news-releases/news-release-details/revance-releases-fourth-quarter-and-full-year-2018-results -Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed- -On track to complete BLA submission with U.S. FDA for glabellar lines indication in the first half of 2019- -Raised approximately $108 million net proceeds from public stock offering on January 22, 2019 - Tue, 26 Feb 2019 16:05:00 -0500 Revance Therapeutics, Inc. News Releases 10396 Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019 https://investors.revance.com/news-releases/news-release-details/revance-release-fourth-quarter-and-full-year-2018-financial Conference Call Scheduled for Tuesday, February 26, 2019 at 4:30pm ET NEWARK, Calif. --(BUSINESS WIRE)--Feb. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today Tue, 12 Feb 2019 16:05:00 -0500 Revance Therapeutics, Inc. News Releases 10351 Revance Announces Closing of Public Offering of Common Stock https://investors.revance.com/news-releases/news-release-details/revance-announces-closing-public-offering-common-stock-1 Gross Proceeds of Offering Total 115.0 Million NEWARK, Calif. --(BUSINESS WIRE)--Jan. 22, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today Tue, 22 Jan 2019 16:05:00 -0500 Revance Therapeutics, Inc. News Releases 10281